Dr Nicholaos Angelopoulos, Endocrinologist,MD,Phd
Abstract
The combination of nutraceuticals based on monacolin allows achieving LDL-C reductions by using lower doses of each component, and thus reduces the likelihood of adverse events re-lated to a single component. Nonetheless, because these supplements contain additional cholesterol-lowering agents, it is challenging to discern whether the lipid-lowering effect was primarily due to monacolin K or another agent.various studies assessing the effects of RYR food supplements containing monacolins yielded safety concerns when the dose of monacolin reached 10 mg/day. The aim of this study is to assess the lipid-lowering activity and safety of a novel, commercially available dietary supplement, containing low dose of monacolin (<3mg) combined with other plant derived ingredients in subjects with moderate elevations in LDL-C concentrations and low cardiovascular risk.